DIRS.INFO The most relevant business & tech news

☆ Bayer calls off break-up to tackle challenges for up to 3 years
▼ + stars: | 2024-03-05 | by ( ) www.cnbc.com time to read: +3 min

The Bayer AG logo sits behind silhouetted members of the management board during the company's annual general meeting in Bonn, Germany, May 25, 2018. The cutbacks will reduce annual costs by 2 billion euros from 2026, it added. To shore up its finances, that German drugmaker has slashed dividends, keeping what analysts estimate would have been combined payouts of 6-7 billion euros over three years. Bayer's net debt at the end of 2023 was up 8.5% to 34.5 billion euros. The company said it would seek to reduce net debt by 1-2 billion this year.

Persons: Bayer, Bill Anderson, Anderson, glyphosate Organizations: Bayer AG, Reuters, Monsanto Locations: Bonn, Germany

☆ Warren Buffett's Berkshire Hathaway keeps buying Liberty's SiriusXM tracking shares. Here's why
▼ + stars: | 2024-01-28 | by ( Yun Li | ) www.cnbc.com time to read: +4 min

Berkshire Hathaway continued to buy Liberty Media's tracking stock for New York-based satellite radio company SiriusXM in a likely merger arbitrage play. Billionaire John Malone's media conglomerate currently owns 84% of Sirius XM and has two tracking stocks that represent that stake in the streaming satellite music service — Liberty Media Corp. Series A shares, or LSXMA , and Liberty Media Corp. Series C shares, or LSXMK . Under the terms of the deal, expected to close early in the third quarter, each Liberty Media Sirius tracking share will be exchanged for 8.4 "new" SIRI shares, while "old" SIRI shareholders would receive new shares in a one-for-one exchange. Berkshire loading up In the past week, Warren Buffett's conglomerate added 438,945 shares of LSXMA and 1 million shares of LSXMK for nearly $45 million combined, according to regulatory filings . Berkshire first bought LSXMK in 2016 and now owns almost 22% of the tracking stock, according to FactSet.

Persons: Berkshire Hathaway, John, SIRI, Warren, Buffett, Ted Weschler, Todd Combs, Seth Klarman's Baupost, SIRI overvalued, Wells, Steven Cahall, Cahall, Jason Bazinet, Charlie Munger, Charlie, hasn't Organizations: Berkshire, Liberty, Sirius XM, — Liberty Media Corp, Liberty Media Corp, Nasdaq, Liberty Media, Liberty Media Sirius, Sirius XM Holdings, Sirius, Citigroup, Activision Blizzard, British Columbia Power, Monsanto, Bayer AG, IBM Locations: New York, Berkshire, LSXMA, LSXMK, Omaha

Those losses ended a nine-trial winning streak for Bayer, shattering investor and company hopes that the worst of the Roundup litigation was over. Her case will help test whether plaintiffs' recent victories were an aberration, or the payoff from favorable court rulings and a shift in plaintiffs' strategy. Plaintiffs' lawyers reject the notion that the evidence about regulators explains their wins. While plaintiffs' lawyers in earlier trials mentioned other chemicals, transcripts of recent closing arguments suggest they have become more prominent. More Roundup trials are expected in 2024.

Persons: Wolfgang Rattay, Kelly Martel, Bayer, Martel, glyphosate, That's, Tom Kline, Jason Itkin, Ernest Caranci, Bart Rankin, Rankin, Brendan Pierson, Alexia Garamfalvi, Bill Berkrot Organizations: Bayer AG, REUTERS, Bayer, U.S, Monsanto, . Environmental Protection Agency, EPA, Union, Health, Thomson Locations: Wuppertal, Germany, Philadelphia, Pleas, Pennsylvania, Europe, New York

☆ Exclusive: Bayer holds call with bond investors after raft of bad news
▼ + stars: | 2023-11-22 | by ( Shankar Ramakrishnan | Thomson Reuters | Shankar Ramakrishnan Has Nearly Years Of Financial Journalism Experience In Writing | ) www.reuters.com time to read: +3 min

The bad news prompted some bond investors to question whether Bayer should sweeten the terms of the deal or outright pull it, one of the sources said. The drug-to-pesticides group priced the investment grade bond on Thursday last week, with the deal closing on Tuesday. Bayer priced bonds with maturities between three to 30 years. It was the 10th largest investment grade bond deal by an industrial company this year and attracted more than $22 billion in orders, according to Informa Global Markets. The events were "not enough to trigger a material adverse change clause in bond documents for investors to ask to be paid back," said CreditSights' Brady.

Persons: Wolfgang Rattay, Bayer, Andrew Brady, CreditSights, JP Morgan, Wells, Brady, Shankar Ramakrishnan, Ludwig Burger, Mike Erman, Paritosh Bansal, Marguerita Choy Organizations: Bayer AG, REUTERS, Bayer, Nomura Holdings, Informa Global Markets, Citigroup, Nikko Securities America, RIC, Thomson Locations: Leverkusen, Germany, Seattle

☆ Monsanto hit with $165 million verdict over PCBs in Seattle school
▼ + stars: | 2023-11-22 | by ( Clark Mindock | Companies Need To Integrate Climate Reporting Across Functions To Comply With California S New Law | Henry Engler | ) www.reuters.com time to read: +2 min

REUTERS/Wolfgang Rattay/File Photo Acquire Licensing RightsNov 21 (Reuters) - A U.S. jury has ordered Bayer's Monsanto to pay $165 million to employees of a school northeast of Seattle who claimed chemicals made by the company called polychlorinated biphenyls, or PCBs, leaked from light fixtures and got them sick. The award included nearly $50 million in compensatory damages, and $115 million in punitive damages. Monsanto said in a statement that it will contest Monday's verdict, and that blood, air and other tests show the school employees were not exposed to unsafe levels of PCBs. PCBs are chemicals once widely used to insulate electrical equipment and in other common products like carbon copy paper, caulking, floor finish and paint. Employees, students and others have claimed in numerous lawsuits against the company that exposure to PCBs at the Sky Valley center caused their cancers, thyroid conditions and other health problems.

Persons: Wolfgang Rattay, Monsanto, Clark Mindock, Alexia Garamfalvi, Richard Chang Organizations: Bayer AG, REUTERS, Monsanto, Sky Valley Education, Thomson Locations: Leverkusen, Germany, U.S, Seattle, Washington, Sky, Monroe , Washington

☆ Bayer stops blood thinner drug trial due to lack of effect, in major setback
▼ + stars: | 2023-11-20 | by ( Ludwig Burger | ) www.reuters.com time to read: +3 min

Logo and flags of Bayer AG are pictured outside a plant of the German pharmaceutical and chemical maker in Wuppertal, Germany August 9, 2019. REUTERS/Wolfgang Rattay/File Photo Acquire Licensing RightsNov 19 (Reuters) - Germany's Bayer (BAYGn.DE) has aborted a large late-stage trial testing a new anti-clotting drug due to lack of efficacy, dealing a fresh blow to the embattled drugmaker and throwing its most promising medium-term development project in doubt. The trial halt, which followed recommendation of independent trial supervisors, marks another setback for a company burdened by a weak herbicide business, high debt and by U.S. lawsuits over the alleged carcinogenic effect of its commonly used Roundup weedkiller. Bayer said it will further analyse the data of the discontinued trial, known as OCEANIC-AF, which was initiated in August 2022. It said the independent trial supervisors recommended the continuation of a separate phase III trial, OCEANIC-STROKE, testing asundexian to prevent repeated strokes in participants who have already suffered one.

Persons: Wolfgang Rattay, Germany's Bayer, Bill Anderson, Bayer, Stefan Oelrich, Johnson, Ludwig Burger, Jose Joseph, Miranda Murray, Christopher Cushing Organizations: Bayer AG, REUTERS, Bristol, Myers Squibb, Johnson, Thomson Locations: Wuppertal, Germany, United States, asundexian, U.S, Frankfurt, Bengaluru

☆ Bayer ordered to pay $1.56 billion in latest US trial loss over Roundup weedkiller
▼ + stars: | 2023-11-19 | by ( Tom Hals | Thomson Reuters | Tom Hals Is An Award-Winning Reporter With Years Of Experience Working In Asia | ) www.reuters.com time to read: +3 min

Logo of Bayer AG is pictured at the annual results news conference of the German drugmaker in Leverkusen, Germany February 27, 2019. Each was diagnosed with non-Hodgkin lymphoma that they alleged was caused by using Roundup on their family property. Bayer has said that decades of studies have shown Roundup and its active ingredient, glyphosate, are safe for human use. The verdict is the fourth straight loss in court for Bayer, after the company had been found not liable to plaintiffs in nine consecutive trials. In 2020, Bayer settled most of the then-pending Roundup cases for up to $10.9 billion.

Persons: Wolfgang Rattay, Bayer, Valorie Gunther, Jimmy Draeger of, Daniel Anderson of, Draeger's, Brenda, Bart Rankin, Forrest Weldon, Tom Hals, Bill Berkrot Organizations: Bayer AG, REUTERS, Bayer, Monsanto, Union Investment, U.S . Environmental Protection Agency, EU Commission, European Food Agency, European Chemicals Agency, Thomson Locations: Leverkusen, Germany, Missouri, Cole County , Missouri, New York, Jimmy Draeger of Missouri, Daniel Anderson of California, Wilmington , Delaware

☆ Bayer Cancels Asundexian Phase III Study Program
▼ + stars: | 2023-11-19 | by ( Nov. | At P.M. | ) www.usnews.com time to read: +1 min

(Reuters) - Germany's Bayer AG said on Sunday it is cancelling a phase III study program to investigate the efficacy and safety of asundexian, an oral Factor XIa (FXIa) inhibitor. The decision to stop the study is based on the recommendation by the Independent Data Monitoring Committee (IDMC). IDMC monitoring showed an inferior efficacy of asundexian compared to the control arm of the study. "A phase III study investigating asundexian compared to Apixaban in patients with atrial fibrillation at risk for stroke is being stopped early," the company said in a statement. Bayer, which initiated the study in August 2022, said it will further analyze the data to understand the outcome and will take appropriate measures.

Persons: Bayer, Jose Joseph, Chris Reese Organizations: Reuters, Germany's Bayer AG, Independent Data Monitoring, Bayer Locations: Bengaluru

☆ Bayer says it is keeping strict line on settling glyphosate litigation
▼ + stars: | 2023-11-08 | by ( ) www.reuters.com time to read: +1 min

The 120 metres high Bayer Cross, logo of German pharmaceutical and chemical maker Bayer AG, consisting of 1710 LED glass bulbs is seen outside the industrial park "Chempark" of the chemical industry in Leverkusen, Germany, September 23, 2023. "We have no appetite to write humongous checks," said CFO Wolfgang Nickl in a media call after the release of third-quarter results. He added that Bayer has sound legal and scientific arguments to pursue its cases and appeals in court. Last week, a California jury found Bayer liable in a case brought by a man who claimed his cancer was due to exposure to the company's glyphosate-based Roundup, the third consecutive defeat for Bayer. Before that, Bayer had won nine cases in a row.

Persons: Wolfgang Rattay, Wolfgang Nickl, Bayer, Ludwig Burger, Miranda Murray Organizations: Bayer, Bayer AG, REUTERS, Rights, Thomson Locations: Leverkusen, Germany, U.S, California

☆ Bayer examines break-up options and prepares to cut management jobs
▼ + stars: | 2023-11-08 | by ( Ludwig Burger | ) www.reuters.com time to read: +3 min

Bayer will remove multiple layers of management and coordination for a "significant reduction" in the workforce, it said. "We are redesigning Bayer to focus only on what’s essential for our mission – and getting rid of everything else," said Anderson. Analysts have said Bayer shares are trading at a massive discount to rivals in agriculture, pharmaceuticals and consumer health activities, partly weighed down by a preference among many financial investors for pure-play companies. Bayer reported third-quarter earnings before interest, tax, depreciation and amortisation (EBITDA) and adjusted for one-off effects fell 31% to 1.685 billion euros, hit by lower earnings at its Crop Science division. Bayer added that it expects a "soft growth outlook and continued challenges" to profitability next year.

Persons: Wolfgang Rattay, Bill Anderson, Anderson, Bayer, Werner Baumann, Ludwig Burger, Miranda Murray, David Goodman Organizations: Bayer AG, REUTERS, Rights, Bayer, Consumer, Roche, Science, Thomson Locations: Leverkusen, Germany

☆ Exclusive-Bayer investor Artisan calls for breakup of company
▼ + stars: | 2023-08-25 | by ( Richa Naidu | Ludwig Burger | ) www.reuters.com time to read: +4 min

Artisan wants the drugs-to-pesticides company to find new owners for its over-the-counter and pharmaceutical units, it said. Before taking over as CEO, Anderson said he was keeping an open mind on whether to break up the company. Artisan is Bayer’s 16th biggest investor, according to Refinitiv data. Samra said the chairman of Bayer’s supervisory board, Norbert Winkeljohann, has not directly written a letter back to Artisan, but said Artisan had “been in contact” with the company. Samra said Artisan “has not suggested specifically how (Bayer) should restructure their business” in the letter.

Persons: “, Wolfgang Rattay, Bill Anderson, Roche, Anderson, ” David Samra, Bayer, ” Samra, they’re, ” Bayer, Werner Baumann, Samra, Norbert Winkeljohann, China’s Syngenta, Johnson Organizations: Bayer, Artisan Partners, Reuters, Bayer AG, REUTERS, Bluebell Capital Partners, Artisan, Artisan’s, Science, pharma, Johnson, GSK Locations: Leverkusen, Germany, Swiss

☆ Exclusive-Bayer investor Artisan calls for break up
▼ + stars: | 2023-08-25 | by ( Richa Naidu | ) www.reuters.com time to read: +1 min

REUTERS/Wolfgang RattayLONDON (Reuters) - Bayer is a “conglomerate” that needs to make major changes including “de-merging” two of its three business arms, investor Artisan Partners told Reuters on Friday. Artisan wants the drugs to-pesticides company to demerge its over-the-counter and pharmaceutical units, it said. “Recently we wrote a letter to the conglomerate Bayer -- and it is a conglomerate,” David Samra, founding portfolio manager of Artisan’s International Value team, said in an interview. Bayer has a “whole host of problems” including “too much debt,” Samra said. Artisan is Bayer’s sixth biggest investor, according to Refinitiv data.

Persons: Wolfgang Rattay, ” David Samra, Bayer, ” Samra, ” Organizations: Bayer AG, REUTERS, Wolfgang Rattay LONDON, Bayer, Artisan Partners, Reuters, Artisan’s Locations: Leverkusen, Germany

The logo of Bayer AG is pictured at the facade of the historic headquarters of the German pharmaceutical and chemical maker in Leverkusen, Germany, April 27, 2020. REUTERS/Wolfgang Rattay Acquire Licensing RightsLONDON, Aug 25 (Reuters) - Bayer (BAYGn.DE) is a "conglomerate" that needs to make major changes including "de-merging" two of its three business arms, investor Artisan Partners told Reuters on Friday. "Recently we wrote a letter to the conglomerate Bayer -- and it is a conglomerate," David Samra, founding portfolio manager of Artisan's International Value team, said in an interview. Bayer has a "whole host of problems" including "too much debt," Samra said. Artisan is Bayer's sixth biggest investor, according to Refinitiv data.

Persons: Wolfgang Rattay, David Samra, Bayer, Samra, Richa Naidu, Matt Scuffham Organizations: Bayer AG, REUTERS, Bayer, Artisan Partners, Reuters, Artisan's, Thomson Locations: Leverkusen, Germany

☆ JPMorgan: The world's food supplies face a bleak future. These are the 3 biggest threats, and the companies best-positioned to tackle food insecurity.
▼ + stars: | 2023-08-25 | by ( Mark Reeth | ) www.businessinsider.com time to read: +10 min

Investors need to know exactly where the threats to the world's food supply are coming from, what themes are beginning to emerge in this new reality, and how they should be investing. New threats to the world's food supplyIn her report, Chang highlighted the ongoing problems affecting the world's food supply: war, weather, and the weaponization of food. One of the most devastating recently implemented restrictions on food supply is India's decision to ban the exportation of non-Basmati white rice. The combination of war, weather, and the weaponization of food has taken a toll on the world's food availability. And within food innovation, JPMorgan analysts like Philippine food and beverage maker Monde Nissin (MONDE PM) and Thailand-based seafood producer Thai Union (TU TB).

Persons: UNICEF — that's, Global Research Joyce Chang, Chang, El, Hilary, CJ Cheiljedang, Mengniu Dairy, Kubota, Jeronimo Martins SGPS Organizations: JPMorgan, Hurricanes, UNICEF —, Global Research, Grain Initiative, Food Policy Research, Food, Agriculture Commodities, ASEAN, Mahindra, LG, Thai Union, TU, Jeronimo Martins SGPS SA, Tesco PLC, J Sainsbury PLC, Koninklijke Ahold Delhaize, Carrefour SA, Yara International ASA, OCI, OCI NA, Bayer AG, PepsiCo Locations: Ukraine, California, Canada, East Coast, Russia, Africa, Asia, India, El, South Korean, HK, South Korea, Philippine, Thailand, Europe

REUTERS/Amit Dave/File PhotoNEW DELHI, July 8 (Reuters) - An Indian court rejected PepsiCo Inc's appeal against an order that revoked a patent for a potato variety grown exclusively for the New York-based company's popular Lay's potato chips. The authority removed PepsiCo's patent cover after Kavitha Kuruganti, a farmers' rights activist, argued that the company cannot claim a patent over a seed variety. PepsiCo petitioned the Delhi High Court against the revocation of the patent cover. In its order dated July 5, Delhi High Court judge Navin Chawla dismissed PepsiCo's appeal against the authority's decision. In 2019, PepsiCo sued some Indian farmers for cultivating the FC5 potato variety, accusing growers of infringing its patent.

Persons: Amit Dave, Kavitha Kuruganti, Navin Chawla, Kuruganti, Mayank Bhardwaj, Sumit Khanna, Kim Coghill Organizations: REUTERS, PepsiCo, New, ' Rights, Authority, Court, Monsanto, drugmaker Bayer AG, Thomson Locations: Ahmedabad, India, DELHI, New York, Delhi, PepsiCo India, U.S

☆ Bayer claims early lead in Parkinson's stem cell therapy
▼ + stars: | 2023-06-28 | by ( Ludwig Burger | ) www.reuters.com time to read: +3 min

Some of this work is done by Britain's' Cambridge University, South Korea's Bundang CHA Hospital, International Stem Cell Corp's (ISCO.PK) Cyto Therapeutics in Australia, the Chinese Academy of Sciences, Harvard University and Japan's Kyoto University Hospital. For BlueRock's experimental therapy, researchers took induced pluripotent stem cells, which are modified to regain the ability to form any type of specialised tissue, and transformed them into dopamine-producing nerve cells. When surgically implanted into the brain of a person with Parkinson's disease, the therapeutic cells are designed to restore neural networks destroyed by the disease. Initial trial results showed the cells multiplied and started making dopamine, an important brain signalling molecule which is lacking in Parkinson's patients. Parkinson's, for which there is no cure and which affects more than 10 million people worldwide, causes progressive brain damage.

Persons: Wolfgang Rattay, Bayer, BlueRock, Britain's, Jennifer Doudna, Ludwig Burger, Miranda Murray, Mark Potter Organizations: Bayer AG, REUTERS, Bayer, Cambridge University, South Korea's, CHA Hospital, Cyto Therapeutics, Chinese Academy of Sciences, Harvard University, Japan's Kyoto University Hospital, BlueRock Therapeutics, Mammoth Biosciences, Thomson Locations: Leverkusen, Germany, FRANKFURT, Australia, San Francisco Bay

Companies Bayer AG FollowNEW YORK, June 15 (Reuters) - Bayer AG (BAYGn.DE) has reached a $6.9 million settlement with New York for allegedly making false and misleading claims regarding the safety of Roundup weedkillers, the state's Attorney General Letitia James said on Thursday. The settlement also requires Bayer and its Monsanto unit to stop advertising that claims Roundup products containing glyphosate are safe and non-toxic. Reporting by Jonathan Stempel in New YorkOur Standards: The Thomson Reuters Trust Principles.

Persons: Letitia James, Jonathan Stempel Organizations: Bayer, Bayer AG, Monsanto, Thomson Locations: New York

Companies Bayer AG FollowNEW YORK, June 15 (Reuters) - Bayer AG (BAYGn.DE) agreed on Thursday to pay $6.9 million to settle claims by New York Attorney General Letitia James that it misled consumers by advertising Roundup weedkiller as safe. The settlement resolves accusations that Bayer and its Monsanto unit failed to substantiate their repeated claims about Roundup products containing the active ingredient glyphosate. These claims included that Roundup "won't harm anything but weeds," and "do not pose a threat to the health of animal wildlife." James said Bayer's and Monsanto's advertising violated state laws against false and misleading advertising, and breached Monsanto's 1996 settlement with New York over its advertising of Roundup at the time. The settlement requires Bayer and Monsanto to stop advertising that glyphosate-based Roundup is safe and non-toxic.

Persons: Letitia James, Bayer, James, Bayer's, Jonathan Stempel, Chizu Organizations: Bayer, Bayer AG, New York, Monsanto, Thomson Locations: New York

Critics have said such awards encourage frivolous lawsuits and excessive fees going to class action attorneys who may seek to benefit their own interests instead. The Supreme Court in 2019 sidestepped resolving a challenge to cy pres awards in a case involving Google. Conservative Justice Clarence Thomas, dissenting in that case, called cy pres settlements "unfair and unreasonable." Monsanto has called the group, which advocates against what it considers abusive class action procedures, a "serial objector to class-action settlements." The group said in court papers that further steps could have taken to distribute the settlement award to class members.

☆ U.S. trade consultations on Mexico's GMO corn rule 'unacceptable violation' of law -Mexican official
▼ + stars: | 2023-04-27 | by ( Adriana Barrera | ) www.reuters.com time to read: +2 min

MEXICO CITY, April 27 (Reuters) - Trade consultations requested by the United States on Mexico's plan to limit the use of genetically modified corn are an "unacceptable violation" of Mexican law and feed the interests of seed "oligopolies," a top Mexican official said on Thursday. The United States, Mexico's main trading partner, requested the consultations in early March under the United States-Mexico-Canada (USMCA) agreement, which calls for a science-based approach to domestic regulations. "The United States' request to Mexico follows the interests of seed, agrochemical, and other food-producing oligopolies," said Mexican Deputy Agriculture Minister Victor Suarez. Washington requested consultations after Mexico softened an original plan to ban GMO corn across the board and instead opened its use for animal feed and industrial use. The Mexican policy "does not affect U.S. corn producers in any way," Suarez said, contradictory to the U.S.' claims.

☆ After growing GM corn for decades, some US farmers open to Mexican restrictions
▼ + stars: | 2023-04-06 | by ( Tom Polansek | ) www.reuters.com time to read: +5 min

"I'm all for free and fair trade," said Fred Huddlestun, who grows GM corn and soybeans in Yale, Illinois. Supporters of the policy say GM corn can contaminate Mexico's age-old native varieties and have questioned its impact on human health. NCGA said GM corn is safe and it will fight all illegal trade barriers for farmers. But many would consider growing more non-GM corn, if the price were right. "You need to make it worth my while," said Illinois farmer Dave Kestel, who grows GM corn and sells seed for Corteva.

☆ Bayer’s New American CEO to Study Wounded Pharma Giant Before Acting
▼ + stars: | 2023-04-05 | by ( William Boston | ) www.wsj.com time to read: 1 min

Bill Anderson joined Bayer’s management board this week and starts as CEO in June. LEVERKUSEN, Germany— Bill Anderson , the American picked to head Bayer AG, treads softly as he begins a monthslong transition into his role as chief executive officer of the German owner of Monsanto, saying he will take his time before trying to fix the company’s most pressing problems. Mr. Anderson, a sprite, athletic 56-year-old hailing from the Gulf coast of Texas, this week joined the management board of Bayer, the 160-year-old chemical and pharmaceutical company known for inventing aspirin more than a century ago. He starts as CEO in June.

☆ Bayer’s New American CEO Treads Softly as He Takes On Wounded Pharma Giant
▼ + stars: | 2023-04-05 | by ( William Boston | ) www.wsj.com time to read: 1 min

REUTERS/Andrew KellyApril 3 (Reuters) - A Delaware judge on Monday dismissed Merck & Co's (MRK.N) lawsuit seeking to hold Bayer AG (BAYGn.DE) responsible for more talc-related liabilities stemming from its $14.2 billion purchase of Merck's consumer care business in 2014. Bayer welcomed the decision, saying that it expected Merck to "take full responsibility for the product claims". "Bayer will continue to defend itself against any further efforts by Merck to avoid or improperly transfer its liabilities to Bayer," the company said in a statement. The $14.2 billion purchase also included Merck's Claritin allergy medicine and Coppertone sunscreen lines. The case is Merck & Co v. Bayer AG, Delaware Chancery Court, No.

A version that was leaked earlier this year showed that Brussels was preparing to shorten an additional period of intellectual property protection, known as data exclusivity, which comes on top of drug patent protection. "The duration of data exclusivity, which may be reduced, could actually have a catastrophic impact for Europe," he said. He said the intentions of Brussels lawmakers - improving patient access to innovative drugs while making the European pharma sector more competitive - were noble but any shortening of intellectual property protection would have the opposite effect. Bayer shares lag'HIGHLY ATTRACTIVE'In the United States, a different set of drug market rule changes are underway, with some of the highest-selling products set to see negotiated price discounts under the Inflation Reduction Act (IRA). Among the biggest drivers was the company's decision to prepare a U.S. launch of its next-generation stroke prevention drug asundexian on its own.

Search resuls for: "Bayer AG"

25 mentions found